TherapeuticsMD (TXMD) Competitors $1.08 -0.03 (-2.67%) Closing price 04:00 PM EasternExtended Trading$1.09 +0.01 (+1.02%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. ATNM, FGEN, TPST, VRCA, LTRN, PEPG, NBRV, RNXT, ATHE, and AADIShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Its Competitors Actinium Pharmaceuticals FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Actinium Pharmaceuticals (NYSE:ATNM) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Is ATNM or TXMD more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -17.94%. TherapeuticsMD's return on equity of -2.01% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% TherapeuticsMD -17.94%-2.01%-1.40% Which has higher earnings and valuation, ATNM or TXMD? TherapeuticsMD has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.24TherapeuticsMD$1.76M7.10-$2.18MN/AN/A Do analysts recommend ATNM or TXMD? Actinium Pharmaceuticals currently has a consensus price target of $4.50, suggesting a potential upside of 177.78%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of ATNM or TXMD? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to ATNM or TXMD? In the previous week, TherapeuticsMD had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for TherapeuticsMD and 0 mentions for Actinium Pharmaceuticals. TherapeuticsMD's average media sentiment score of 1.45 beat Actinium Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the news media. Company Overall Sentiment Actinium Pharmaceuticals Neutral TherapeuticsMD Positive Which has more risk and volatility, ATNM or TXMD? Actinium Pharmaceuticals has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. SummaryTherapeuticsMD beats Actinium Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.50M$2.83B$5.75B$10.28BDividend YieldN/A57.24%5.72%4.60%P/E RatioN/A23.2874.9926.41Price / Sales7.10529.36456.1088.49Price / CashN/A27.5625.8129.91Price / Book0.465.4013.256.28Net Income-$2.18M$32.95M$3.29B$270.38M7 Day PerformanceN/A0.20%0.46%2.69%1 Month Performance-7.68%4.10%4.59%5.98%1 Year Performance-39.66%-2.91%73.41%25.93% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD1.4765 of 5 stars$1.08-2.7%N/A-38.0%$12.50M$1.76M0.00420Short Interest ↓ATNMActinium Pharmaceuticals2.2131 of 5 stars$1.60+1.3%$4.50+181.3%-12.4%$49.91MN/A-1.1530FGENFibroGen4.4697 of 5 stars$11.16-7.8%$43.00+285.3%+2.4%$48.93M$29.62M-29.37570News CoverageAnalyst UpgradeGap DownTPSTTempest Therapeutics2.4638 of 5 stars$10.85-1.3%$30.00+176.5%-45.6%$48.80MN/A-0.7420Positive NewsVRCAVerrica Pharmaceuticals4.0802 of 5 stars$5.06-1.0%$80.00+1,481.0%-75.9%$48.22M$7.57M-0.6140LTRNLantern Pharma2.3671 of 5 stars$4.06-5.8%$25.00+515.8%-4.7%$46.54MN/A-2.2820PEPGPepGen2.8361 of 5 stars$1.49+6.4%$7.67+414.5%-84.4%$45.92MN/A-0.5030NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3436 of 5 stars$1.14-8.1%$7.50+557.9%+13.7%$45.44M$40K-3.006Short Interest ↑Gap UpATHEAlterity Therapeutics2.481 of 5 stars$5.17+2.0%$12.00+132.1%+287.3%$44.96MN/A0.0010News CoverageGap UpHigh Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+10.6%$44.95M$25.07M-0.8040 Related Companies and Tools Related Companies Actinium Pharmaceuticals Alternatives FibroGen Alternatives Tempest Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Lantern Pharma Alternatives PepGen Alternatives Nabriva Therapeutics Alternatives RenovoRx Alternatives Alterity Therapeutics Alternatives Aadi Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TXMD Stock Alerts